Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 810 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Saline Solution Intravenous Infusion Clear all
Terminated Phase 3 Interventional Results available

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

NCT01176565
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Intravenous nicardipine hydrochloride
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
116
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Phase 2 Interventional Results available

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

NCT00238433
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, busulfan, melphalan, thiotepa, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 9, 2026, 1:20 PM EDT
Terminated Phase 3 Interventional Results available

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

NCT02697292
View directory record Official record
Conditions
Autoimmune Epilepsy
Interventions
Intravenous Immunoglobulin, Placebos, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Not applicable Interventional Results available

Lidocaine and Prevention of Chronic Pain

NCT01619852
View directory record Official record
Conditions
Surgery
Interventions
.9 normal saline placebo, Group L (lidocaine)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery

NCT00701636
View directory record Official record
Conditions
Late Effects of Surgery, Staphylococcus Aureus, Surgical Site Infection
Interventions
daptomycin
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
19 Years to 74 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2016 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

NCT00843193
View directory record Official record
Conditions
Asthma
Interventions
INTRAVENOUS GSK679586, INTRAVENOUS PLACEBO, FLUTICASONE PROPIONATE
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Medford, Oregon • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Phase 3 Interventional Results available

Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children

NCT00857727
View directory record Official record
Conditions
Agitation, Anesthesia, Pediatrics
Interventions
Dexmedetomidine, Saline
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
6 Months to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
(2R,6R)-Hydroxynorketamine hydrochloride, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Sep 9, 2026, 1:20 PM EDT
Not yet recruiting Phase 2 Interventional

Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

NCT07674745
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin, Treatment as Usual
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
9
States / cities
Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 9, 2026, 1:20 PM EDT
Terminated Phase 2 Interventional Results available

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

NCT01453088
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Bortezomib
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
60 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 9, 2026, 1:20 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy

NCT01093131
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
Oral hydration, Oral sodium bicarbonate, Intravenous Hydration, Intravenous sodium bicarbonate
Other · Drug
Lead sponsor
The Western Pennsylvania Hospital
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 9, 2026, 1:20 PM EDT
Withdrawn Phase 2 Interventional

Effect of Perioperative Intravenous Lidocaine on Postoperative Quality of Recovery in Patients Undergoing Spine Surgery

NCT01930877
View directory record Official record
Conditions
Pain
Interventions
Lidocaine, Placebo (normal saline)
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Sep 9, 2026, 1:20 PM EDT
Active, not recruiting Early Phase 1 Interventional

Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)

NCT04846829
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, intermittent theta burst stimulation, intravenous citalopram hydrochloride (CIT), continuous theta burst stimulation
Drug · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Phase 1 Interventional

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

NCT00620295
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
bortezomib, gemcitabine hydrochloride
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
70 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 9, 2026, 1:20 PM EDT
Recruiting Phase 1 Interventional

IS-free Treg HaploHCT

NCT04678401
View directory record Official record
Conditions
Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute, Myeloid Leukemia in Relapse (Disorder), Myelodysplastic Syndromes
Interventions
Radiation, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Treg-enriched donor cell, Unmodified donor T Cell, CD34+ Haplo Peripheral Blood Stem Cell, Melphalan
Radiation · Drug · Biological + 1 more
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Phase 4 Interventional Results available

PO vs. IV Acetaminophen Given Perioperatively for 24 hr Post-op Pain Control Following Total Hip or Knee Replacement

NCT02244619
View directory record Official record
Conditions
Post-op Pain
Interventions
Oral acetaminophen, IV acetaminophen
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2017 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

NCT01264783
View directory record Official record
Conditions
Myocardial Infarct
Interventions
RNS60, Placebo
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Phase 2 Interventional

Investigation of Sleep in the Intensive Care Unit

NCT03355053
View directory record Official record
Conditions
Delirium, Sleep
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

NCT01147302
View directory record Official record
Conditions
Graft Rejection
Interventions
Placebo, C1 Esterase Inhibitor (Human)
Biological
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Autonomic Nervous System and Nitric Oxide Interactions

NCT01137253
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Trimethaphan, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Intravenous Anesthetics on Fear Learning and Memory

NCT00767767
View directory record Official record
Conditions
Phobias
Interventions
Placebos, Propofol 0.45mcg/mL, Propofol 0.90mcg/mL, Thiopental 1.5mcg/mL, Thiopental 3mcg/mL
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 9, 2026, 1:20 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke

NCT04818944
View directory record Official record
Conditions
Acute Ischemic Stroke, Ischemic Stroke
Interventions
Tirofiban Hydrochloride, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Not applicable Interventional Results available

The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy

NCT01450813
View directory record Official record
Conditions
Anesthesia, Neuromuscular Blockade
Interventions
Saline 0.06 ml/kg, Rocuronium 0.2 mg/kg, Rocuronium 0.4 mg/kg, Rocuronium 0.6 mg/kg
Drug
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 9, 2026, 1:20 PM EDT
Completed Phase 2 Interventional

Double Blind Trial in Children With Autism Spectrum Disorder

NCT06058962
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Suramin Sodium
Drug
Lead sponsor
Paxmedica
Industry
Eligibility
4 Years to 17 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 9, 2026, 1:20 PM EDT